Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

Israel - hebreu - Ministry of Health

unipharm ltd, israel - valsartan - טבליה - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - hebreu - Ministry of Health

novartis pharma services ag - amlodipine as besylate 5 mg; valsartan 320 mg - film coated tablets - valsartan - exforge ( amlodipine and valsartan) is insicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension.